AIN457S
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $767,948 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $767,948 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SECUKINUMAB 300 MG OVER 32 WEEKS IN ADULT PATIENTS WITH BIOPSY-PROVEN FORMS OF LICHEN PLANUS NOT ADEQUATELY CONTROLLED WITH TOPICAL THERAPIES - PRELUDE | Novartis Pharmaceuticals Corporation | $767,948 | 0 |
Top Doctors Receiving Payments for AIN457S
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cromwell, CT | $767,948 | 14 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $767,948
Product Information
- Type Drug
- Total Payments $767,948
- Total Doctors 0
- Transactions 14
About AIN457S
AIN457S is a drug associated with $767,948 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $767,948 was paid across 14 transactions to 0 doctors.
The most common payment nature for AIN457S is "Unspecified" ($767,948, 100.0% of total).
AIN457S is associated with 1 research study, including "A PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SECUKINUMAB 300 MG OVER 32 WEEKS IN ADULT PATIENTS WITH BIOPSY-PROVEN FORMS OF LICHEN PLANUS NOT ADEQUATELY CONTROLLED WITH TOPICAL THERAPIES - PRELUDE" ($767,948).